Benlysta (Belimumab) Injection

Description

Benlysta (Belimumab) is a human monoclonal antibody medication developed to treat systemic lupus erythematosus (SLE) and lupus nephritis. The drug works by blocking B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS), which is involved in autoimmune diseases like lupus. By targeting and neutralizing BAFF, Benlysta helps reduce the symptoms and severity of lupus.

Directions

Benlysta is administered through IV infusions or subcutaneous injections, depending on the prescribed form. Before using Benlysta, it’s important to receive proper training from a healthcare provider on the correct way to use the autoinjector for the subcutaneous form of the drug.

The standard dosage for the IV infusion form of Benlysta is a 10 mg/kg dose every 2 weeks for the first three doses, and then every 4 weeks thereafter. For the subcutaneous form, the standard dosage is 200 mg injected once per week. Follow your healthcare provider's instructions to ensure the proper Benlysta dosing schedule.

Ingredients

The main ingredient in Benlysta is Belimumab. In addition to the active ingredient, Benlysta contains various inactive ingredients, such as citric acid, polysorbate 80, sodium citrate, and sucrose.

Contraindications

Avoid taking or using Benlysta if any of the following apply:

• This medication has not been evaluated in patients with severe active central nervous system lupus and thus may not be safe or effective in such cases.
• The use of Benlysta in combination with other biologic therapies is not recommended, as it has not been studied in these situations.
• Using this medication in patients with a known hypersensitivity can cause serious adverse reactions, including anaphylaxis.

Cautions

• Before starting Benlysta, inform your doctor about:
• Any medications you take, especially other biologics, as their combined use is not recommended.
• Pre-existing medical conditions, such as severe active central nervous system lupus, as Benlysta has not been evaluated for these situations.
• If you have experienced allergic reactions to any medications.

• Benlysta has been linked to serious and occasionally fatal infections due to its immunosuppressive nature. Use with caution if you have a history of chronic or severe infections, and report any new infections that occur during treatment.
• Be vigilant for new, changing, or worsening neurological symptoms, which may signal progressive multifocal leukoencephalopathy (PML). If PML is diagnosed, Benlysta and other immunosuppressive drugs should be stopped immediately.
• Serious allergic reactions, including anaphylaxis, are possible. Seek emergency help if symptoms of a severe allergic reaction develop.
• Depression and thoughts of suicide have been reported. Have a mental health assessment before starting Benlysta and maintain regular checks for any mood changes, depression, or suicidal thoughts during therapy.
• Live vaccines are not recommended with Benlysta. Ensure a complete vaccine history is provided to your healthcare provider and discuss any upcoming vaccinations.

Side Effects

Benlysta can cause a variety of side effects. Some common Benlysta side effects include nausea, diarrhea, fever, cough, headaches, insomnia, depression, and arm or leg pain. In addition, some people may experience pain, redness, or swelling around the area of injection.

Benlysta can also cause more serious side effects, which require immediate medical attention. Examples include symptoms of an allergic reaction, such as swelling in the face or throat, trouble breathing, and rash. If you or someone you know is taking Benlysta and experiences any of these severe side effects, seek medical help promptly.

References:

1. Benlysta (Belimumab) Product Monograph. Durham, NC: GlaxoSmithKline; 2023.
2. Benlysta (Belimumab) Drug Label Information. Durham, NC: GlaxoSmithKline; 2023.

About Dr. Gerardo Sison (Page Author)

An honors graduate of the University of Florida, Dr. Sison started his pharmacy career in a community setting, extending his services to hospitals and clinics over time. He has also worked in medication therapy management, advising patients on proper medication use for their chronic health conditions. Read More....